Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
Sadaf AliShanat BaigSubadra WanninayakeGabriela da Silva XavierCharlotte DawsonRichard PaiseyTarekegn GeberhiwotPublished in: Diabetes, obesity & metabolism (2023)
Data from our centre highlight the non-inferiority of GLP-1 RAs in monogenic syndromic obesity to the available GLP-1 RA-use data in polygenic obesity, therefore, these agents can be considered as a treatment option in patients with ALMS, as well as other forms of monogenic obesity.
Keyphrases
- insulin resistance
- weight loss
- metabolic syndrome
- high fat diet induced
- type diabetes
- weight gain
- electronic health record
- end stage renal disease
- chronic kidney disease
- big data
- intellectual disability
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- skeletal muscle
- peritoneal dialysis
- body mass index
- physical activity
- machine learning
- systemic sclerosis
- autism spectrum disorder
- replacement therapy
- disease activity